Assessment of Safety of Air Travel in Patients With Birt-Hogg-Dube Syndrome
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03040115|
Recruitment Status : Unknown
Verified January 2017 by Nishant Gupta, University of Cincinnati.
Recruitment status was: Recruiting
First Posted : February 2, 2017
Last Update Posted : February 2, 2017
|Condition or disease||Intervention/treatment|
|Birt-Hogg-Dube Syndrome||Other: Non-Interventional Study|
|Study Type :||Observational [Patient Registry]|
|Estimated Enrollment :||100 participants|
|Target Follow-Up Duration:||3 Years|
|Official Title:||Assessment of Safety of Air Travel in Patients With Birt-Hogg-Dube Syndrome|
|Study Start Date :||August 2015|
|Estimated Primary Completion Date :||December 2018|
|Estimated Study Completion Date :||December 2018|
- Incidence of spontaneous pneumothorax during or within 24 hours following air travel [ Time Frame: 3 years ]The investigators will measure the number of pneumothoraces that occur either during air travel, or within 24 hours of air travel among patients with Birt-Hogg-Dube syndrome. The incidence of air travel related pneumothorax will be calculated by dividing the number of pneumothoraces to the total number of flights undertaken by the entire cohort.
- Rate of recurrent pneumothorax in patients with Birt-Hogg-Dube syndrome [ Time Frame: 3 years ]The investigators will catalogue the number roof spontaneous pneumothoraces experienced by patients with Birt-Hogg-Dube syndrome. These results will be used to calculate the proportion of patients who experience at least one recurrence of their pneumothorax, as well as the average number of pneumothoraces experienced per patient.
- Efficacy of pleurodesis in reducing the risk of recurrent pneumothoraces in Birt-Hogg-Dube syndrome [ Time Frame: 3 years ]The investigators will measure the incidence of ipsilateral pneumothorax following pleurodesis in order to determine the efficacy (as measured by the rate of pneumothorax recurrence following pleurodesis). These results will be calculated separately for chemical and surgical pleurodesis.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03040115
|Contact: Elizabeth J Kopras, BAfirstname.lastname@example.org|
|United States, Ohio|
|University of Cincinnati||Recruiting|
|Cincinnati, Ohio, United States, 45267|
|Contact: Elizabeth J Kopras, BA 513-558-7205 email@example.com|
|Principal Investigator: Nishant Gupta, MD|